H. Meyer (1983). Structure–activity relationships in calcium antagonists. In: L. R. Opie (Ed.).
Calcium Antagonists and Cardiovascular DiseaseNew York: Raven Press.
M. Noda, S. Shimizu, T. Tanabe, T, Takai, T. Kayano, T. Ikeda, H. Takahashi, H. Nakayama,
Y. Kanaoka, N. Minamino (1984). Primary structure of Electrophorus electricus sodium
channel deduced from cDNA sequence. Nature 312: 121–127.
M. A. Perillo (2002). The drug–membrane interaction: its modulation at the supramolecular level.
Recent Res. Dev. Biophys. Chem. 2: 105–121.
H. J. Reiser, M. E. Sullivan (1986). Antiarrhythmic drug therapy: new drugs and changing con-
cepts.Fed. Proc. 45: 2206–2208.
E. Rucker (1987). Structure, function and assembly of membrane proteins. Science 235: 959–961.
G. Schneider, W. Neidhart, G. Adam (2001). Integrating virtual screening methods to the quest
for novel membrane protein ligands. Current Medicinal Chemistry: Central Nervous System
Agents 1: 99–112.
R. R. Schofield, M. G. Darlison, N. Fujita, D. R. Burt, F. H. Stephenson, H. Rodrigues,
L. M. Rhee, J. Ramachandran, V. Reale, T. A. Glencorse, P. H. Seeburg, E. A. Barnard (1987).
Sequence and functional expression of the GABA receptor shows a ligand-gated receptor
super-family. Nature 328: 221–227.
M. Spedding (1985). Calcium antagonist subgroups. Trends Pharmocol. Sci. 6: 109–114.
M. I. Steinberg, W. B. Lancefield, D. W. Robinson (1986). Class I and III antiarrhythmic drugs.
Annu. Rep. Med. Chem. 21: 95–108.
C. F. Stevens (1987). Channel families in the brain. Nature 328: 198–199.
D. J. Triggle, R. A. Janis (1987). Calcium channel ligands. Annu. Rev. Pharmacol. Toxicol. 27 :
347–369.
E. Wehinger, R. Gross (1986). Calcium modulators. Annu. Rep. Med. Chem. 21: 85–94.
Cell Nucleus Targets
G. L. Chen, L. F. Liu (1986). DNA topoisomerases as therapeutic targets in cancer chemother-
apy. Annu. Rep. Med. Chem. 21: 257–262.
S. T. Crooke, A. W. Prestayko (Eds.) (1981). Cancer and Chemotherapy, vol. 3:Antineoplastic
Agents. New York: Academic Press.
T. W. Doyle, T. Kaneko (1985). Antineoplastic agents. Annu. Rep. Med. Chem. 20: 163–172.
J. B. Gibbs (2000). Mechanism-based target identification and drug discovery in cancer research.
Science 287: 1969–1973.
T. Morisaki, M. Katano (2003). Mitochondria-targeting therapeutic strategies for overcoming
chemoresistance and progression of cancer. Curr. Med. Chem. 10: 2517–2521.
R. Z. Murray, C. Norbury (2000). Proteasome inhibitors as anti-cancer agents. Anti-Cancer
Drugs 11: 407–417.
D. C. Myles (2002). Emerging microtubule stabilizing agents for cancer chemotherapy. Annu.
Rep. Med. Chem. 37: 125.
S. Neidle (1979). The molecular basis of action of some DNA-binding drugs. In: G. P. Ellis and
G. B. West (Eds.). Progress in Medicinal Chemistry, Vol. 16. Amsterdam: Elsevier/North
Holland, pp. 151–221.
W. B. Pratt, R. W. Ruddon (1979). The Anticancer Drugs.New York: Oxford University Press.
W. E. Ross (1985). DNA topoisomerases as targets for cancer therapy. Biochem. Pharmacol. 34 :
4191–4195.
A. C. Sartorelli, D. G. Johns (Eds.) (1974, 1975). Antineoplastic and Immunosuppressive Agents,
Parts 1 and 2. New York: Springer.
K. Shimizu, N. Oku (2004). Cancer anti-angiogenic therapy. Biol. Pharmaceut. Bull. 27: 599–605.
F. Takusagawa, R. Carlson, R. F. Weaver (2001). Anti-leukemia selectivity in actinomycin analogues.
Bioorg. Med. Chem. 9: 719–725.
464 MEDICINAL CHEMISTRY